Indefinite Delivery Contract SPE2DU25D9132

The federal contract IDV award SPE2DU25D9132 is a single-award Indefinite Delivery Contract (IDC) valued at $4,999,999.00 and awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract covers a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the medical supply needs of military health facilities worldwide. The IDC has an ultimate completion date of December 31, 2036 and enables the DLA to issue firm fixed-price delivery orders for these pharmaceutical items across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. This contract aligns with the DLA's upcoming Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which aims to establish multiple regional prime vendor contracts valued at an estimated $30.3 billion to provide worldwide pharmaceutical support to DoD customers, the U.S. Coast Guard, and other government agencies. The PPV-G GEN V solicitation is expected to be issued in March 2024 with no set-aside designations, allowing DMS Pharmaceutical Group to leverage its WOSB status to secure this significant federal contract award.